Orca Bio

Head, Site Onboarding & Market Enablement

Remote

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

The Head, Site Onboarding & Market Enablement should have experience in developing and implementing scalable models and processes for site onboarding, treatment center certification, and institutional support. This role requires cross-functional collaboration with commercial, operational, and clinical teams, and the ability to manage a growing team. Proficiency in using CRM and analytics tools for customer segmentation, regional account targeting, data analysis, and reporting is essential. Experience with AI-driven analytics and visualization tools, as well as embedding compliance requirements into workflows, is also necessary. Approximately 30% travel is expected.

Responsibilities

This role is responsible for driving the execution of Orca Bio’s treatment center onboarding, activation, and ongoing site engagement to ensure operational readiness for ORCA-T administration. Key responsibilities include building and managing relationships with treatment center leadership, operational staff, and KOLs, and leading institutional engagement initiatives by creating and delivering tools, resources, and training sessions. The position will partner with Site Profiling to design and maintain treatment center segmentation and prioritization models, and contribute to analysis and decision-making for activation strategies. Additionally, the role involves refining customer segmentation and regional account targeting using CRM and analytics tools, integrating data sources to identify and prioritize KOLs, and translating national strategies into regional execution plans with digital playbooks, workflows, and campaign assets. Responsibilities also include developing and maintaining resources, messaging, and workflows within CRM and enablement tools, tracking account and KOL engagement through CRM dashboards, producing and maintaining shared CRM reporting and insights, and training Regional Marketers on CRM best practices. The role will also apply AI-driven analytics to uncover trends and optimize strategies, and embed compliance requirements into CRM workflows and digital processes. Finally, the position will partner with Supply Chain, Quality, and Case Management to manage 3PL relationships.

Skills

Cell Therapy
Onboarding
Market Enablement
Treatment Center Operations
Relationship Management
Strategy Development
Process Improvement
Cross-functional Collaboration
Team Management
Training Delivery
KOL Engagement

Orca Bio

Develops and commercializes cell therapies

About Orca Bio

Orca Bio operates in the biotechnology sector, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company works to enhance these therapies, aiming to make them safer and more effective for patients. Orca Bio's products are primarily used by healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to improve patient outcomes through advanced cell therapies, addressing conditions that currently have limited treatment options.

Menlo Park, CaliforniaHeadquarters
2016Year Founded
$186.8MTotal Funding
SERIES_DCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
Parental Leave

Risks

Emerging competition from BlueRock Therapeutics in stem cell therapies.
Aspen Neuroscience's advancements in personalized stem cell therapies pose a threat.
Competitors' focus on iPSC-derived therapies may overshadow Orca Bio's offerings.

Differentiation

Orca Bio focuses on high-precision cell therapies for cancer and autoimmune diseases.
Their lead product, Orca-T, shows promising relapse-free survival rates in clinical trials.
Orca Bio's therapies aim to replace diseased blood and immune systems with healthy ones.

Upsides

Orca-T demonstrated 87% relapse-free survival in a Phase 1b/2 trial.
FDA's expedited approval pathways could accelerate Orca Bio's market entry.
Advancements in gene editing enhance the efficacy of Orca Bio's cell therapies.

Land your dream remote job 3x faster with AI